Immune evasion through mitochondrial transfer in the tumour microenvironment
Hideki Ikeda(Chiba University), Yosuke Togashi(Okayama University), Yoshiyasu Umeda(Saitama Medical University), Jason Lin(Chiba Cancer Center), Yukiko Kiniwa(Shinshu University), Toyoyuki Hanazawa(Chiba University), Tsuyoshi Osawa(The University of Tokyo), Katsushige Kawase(Chiba University), Shinichi Toyooka(Okayama University Hospital), Yusuke Suenaga(Chiba Cancer Center), Takao Morinaga(Chiba Cancer Center), Masahito Kawazu(Chiba Cancer Center), Hidetoshi Hayashi(Kindai University), Takashi Inozume(Chiba University), Youki Ueda(Okayama University), Takehiro Ohnuma(University of Yamanashi), Yasuhiro Nakamura(Mitsubishi Electric (Germany)), Keizo Takenaga(Chiba Cancer Center), Tatsuyoshi Kawamura(University of Yamanashi), Eiki Ichihara(Okayama University), Tomofumi Watanabe(Okayama University), Shinichiro Suzuki(Kindai University), Sho Aki(The University of Tokyo), Shusuke Kawashima(Chiba University), Yasutoshi Tatsumi(Chiba Cancer Center), Hideki Makinoshima(National Institute of Technology, Tsuruoka College), Joji Nagasaki(Osaka City University), Akiko Honobe‐Tabuchi(University of Yamanashi), Hiroyuki Mano(National Cancer Research Institute), Makiko Itami(Chiba Cancer Center), Yuki Nakamura(Thomas Jefferson University), Takuji Suzuki(Chiba University), Tatsuya Nishi(Okayama University), Jun‐ichiro Ikeda(Chiba University Hospital), Takamasa Ishino(Chiba University)
Cited by 239
Related Papers
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
|JAMA Oncology|2017|1k
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments
|Cancer Cell|2022|828
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
|Nature Immunology|2020|810
Prospective Phase II Study of Gefitinib for Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer With Epidermal Growth Factor Receptor Gene Mutations
|Journal of Clinical Oncology|2006|504
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
|Nature Medicine|2020|393